Eli Lilly Valuation
| LLY Stock | MXN 16,249 78.27 0.48% |
At this time, the firm appears to be overvalued. Eli Lilly shows a prevailing Real Value of 13862.34 per share. The current price of the firm is 16248.73. Our model computes the value of Eli Lilly from reviewing the firm fundamentals such as Profit Margin of 0.22 %, shares outstanding of 950.18 M, and Current Valuation of 6.99 T as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16248.73 | Real 13862.34 | Hype 16248.73 | Naive 16962.09 |
The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eli Lilly's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eli Lilly and helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors: Eli Lilly Total Value Analysis
Eli Lilly and is now anticipated to have takeover price of 6.99 T with market capitalization of 6.16 T, debt of 15.35 B, and cash on hands of 2.2 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Eli Lilly fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.99 T | 6.16 T | 15.35 B | 2.2 B |
Eli Lilly Investor Information
About 85.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.23. Eli Lilly recorded earning per share (EPS) of 123.49. The entity last dividend was issued on the 14th of February 2023. Based on the key measurements obtained from Eli Lilly's financial statements, Eli Lilly and is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Eli Lilly Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eli Lilly has an asset utilization ratio of 58.48 percent. This suggests that the Company is making 0.58 for each dollar of assets. An increasing asset utilization means that Eli Lilly and is more efficient with each dollar of assets it utilizes for everyday operations.Eli Lilly Ownership Allocation
Eli Lilly holds a total of 950.18 Million outstanding shares. The majority of Eli Lilly and outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eli Lilly to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eli Lilly. Please pay attention to any change in the institutional holdings of Eli Lilly and as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eli Lilly Profitability Analysis
The company reported the revenue of 28.54 B. Net Income was 6.24 B with profit before overhead, payroll, taxes, and interest of 21.91 B.About Eli Lilly Valuation
Our relative valuation model uses a comparative analysis of Eli Lilly. We calculate exposure to Eli Lilly's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eli Lilly's related companies.Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 33610 people.
8 Steps to conduct Eli Lilly's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Eli Lilly's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Eli Lilly's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Eli Lilly's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Eli Lilly's revenue streams: Identify Eli Lilly's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Eli Lilly's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Eli Lilly's growth potential: Evaluate Eli Lilly's management, business model, and growth potential.
- Determine Eli Lilly's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Eli Lilly's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.